Immune cell therapy takes on stubborn muscle weakness
NCT ID NCT07243366
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new treatment for people with refractory myasthenia gravis, a condition causing severe muscle weakness. The treatment uses donor immune cells (CAR-NK cells) engineered to target and calm the immune system's attack on muscles. Fifteen participants will receive infusions every two weeks for 24 weeks, with researchers monitoring safety and any changes in daily living and muscle strength.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD19-CAR-NK cells (immune cells engineered to target CD19)
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-control myasthenia gravis.
- What could go wrong
- This is a very early, small trial (15 people) testing safety first. The treatment may not improve symptoms, and side effects from the immune cells are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.